How much funding has IDRx raised?

IDRx has raised $122.0M in total funding, most recently a Series A round.

Who are IDRx's investors?

IDRx's investors include Andreessen Horowitz.

Where is IDRx headquartered?

IDRx is headquartered in Cambridge, Massachusetts, United States.

IDRx

Home | GSK

Cambridge, United States · Founded 2021 · $122.0M raised

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 11–50
Founded: 2021
Business Model: B2B

Website: idrx.com
Total Funding: $122.0M
Last Round: $122.0M Series AAug 2022
Rounds: 1

About

IDRx was a clinical-stage biopharmaceutical company developing precision oncology therapies for gastrointestinal stromal tumors (GIST). Its lead asset IDRX-42, a highly selective KIT inhibitor licensed from Merck KGaA, demonstrated activity against all clinically relevant primary and secondary KIT mutations. IDRx was founded in 2021 by Alexis Borisy, George Demetri, and Nicholas Lydon, and was acquired by GSK in February 2025 for approximately $1 billion upfront.

Summary

IDRx is a Healthcare company based in Cambridge, United States, founded in 2021. It has raised $122.0M in total across 1 round, most recently a $122.0M Series A round in Aug 2022. Investors include Andreessen Horowitz.

LinkedIn X (Twitter)